Hematologist, with a focus on hematopoietic cell transplantation and hematopoietic cellular therapies. Therapeutic innovations. Head & qualified person: Centre de Therapie Cellulaire, Institut Paoli-Calmettes Comprehensive Cancer Centre. Professor of Medicine in Cell Biology at Aix-Marseille Université School of Medicine. Coordinating physician of the "Centre d'Investigations Cliniques en Biothérapies" Inserm-AMU-AP-HM-IPC, all in Marseilles, France.

Professor Thomas Cluzeau (MD, PhD) is head of the Hematology Department at the Centre Hospitalier Universitaire de Nice (CHU), France (member of Cote d'Azur University). His research interests include myelodysplastic syndromes and acute leukemia (including myeloid and lymphoid). He performs basic and translational sciences in the Mediterranean Center of Molecular Medicine (INSERM U1065), Nice, France, with international collaborations (including Moffitt Cancer Center and Research Institute, Tampa, FL, USA). He is a member of several French cooperative groups and is active in clinical research in the Groupe Francophone des Myélodysplasies (GFM), the Acute Leukemia French Association (ALFA) and the Group for Research in Adult Lymphoblastic Leukemia (GRAALL).

I am a medical doctor working as a consultant hematologist at the First-in-human/Phase 1 unit, Center for Clinical Cancer Studies, at Karolinska University Hospital, Stockholm, Sweden. I am also currently completing my PhD-work in Professor Eva Hellström Lindberg group at Karolinska Institutet. My main research focus is on the genetic lanscape and prognostic markers of Myelodysplastic Syndromes.

CURRENT JOB POSITION AND ORGANIZATION Professor of Hematology - Humanitas University Milan, Italy Head, Leukemia Unit - Cancer Center - IRCCS Humanitas Research Hospital www.humanitas.it; www.hunimed.eu Head - Center for Accelerating Leukemia/Lymphoma Research – CALR Humanitas AI center, Milan Italy www.humanitas.eu; www.humanitas.eu/calr/ PROFESSIONAL SUMMARY Current research interests mainly concern myeloid malignancies (myelodysplastic syndromes, MDS acute myeloid leukemias AML, myeloproliferative neoplasms, MPN): - Genomics of myeloid neoplasms - Diagnosis and prognostication of myeloid neoplasms - Personalized medicine - Artificial Intelligence in hematology - Decision Support Systems

Dr. Amy DeZern is a hematologist and an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. Dr. DeZern’s primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of aplastic anemia (AA), myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) as well as acute leukemias. She is an active clinician scientist who specializes in clinical trials of diagnostics and therapeutics for these disorders. She has been the principle investigator for over 40 single center and multicenter clinical trials in MDS and AA. These investigator-led initiatives focus is on transplant therapies in AA (including the upcoming BMT CTN upfront trial for SAA) and novel therapeutics (Phase 1-3 trials) in MDS. Additionally, Dr. DeZern is the deputy co-chair of The National MDS Study.

I am a Biochemist and Molecular Biologist (University of the Basque Country, 2015-19) specialised in Basic and Translational Research in Cancer (MSc in Biomedicine, University of Barcelona, 2019-20). I am currently doing my PhD studies in Applied Medicine and Biomedicine, at University of Navarra (2020-ongoing), in the fields of Computational Biology and Hemato-Oncology. Concretely, my project is based on identifying transcriptional alterations in MDS and AML that could serve as potential therapeutic targets for these patients.

After graduating from medical school in 1999, Prof. Díez Campelo started medical training in Hematology. Since 2005, she has been working at the Department of Hematology at the University Hospital of Salamanca, IBSAL in Spain. Between 2006 and 2009 she completed a 3-year postdoctoral fellowship provided by ISCII. From 2009 was responsible of the section of Morphology and Hematimetry in the Hematology Department and since 2017 Prof. Díez Campelo held a position of Associate Professor of Hematology at the University of Salamanca in Spain. Since October 2016 Prof. Díez Campelo is heading the Myelodysplastic Syndromes team at the University Hospital in Salamanca. Prof. Díez Campelo´s clinical expertise lies in hematological malignancies with a focus on MDS and AML. The main scientific interest involves the translational exploration of innovative treatment options for these patients. She is a member of the Spanish MDS group (GESMD) since 2009 and head of GESMD since 2018. She also is involved in the European Myelodysplastic Syndromes Cooperative Group (EMSCO).